Marc Grasso, M.D., is the Chief Financial Officer (CFO) at Kyverna Therapeutics, and is responsible for overseeing Finance, Legal, Information Technology and Facilities. Marc brings more than 25 years of public company, capital markets, and investment banking management experience to the role, having previously served as both a CFO and as a senior leader in some of the world’s leading biotech and healthcare investment banking businesses.

Prior to joining Kyverna, Marc was the CFO for Alector, Inc., a late-stage clinical biotechnology company focused on neurodegenerative diseases. He also served as CFO and Chief Business Officer of Kura Oncology, another clinical-stage biopharmaceutical company focused on precision medicines for the treatment of cancer. At these companies, Dr. Grasso was instrumental in optimizing capital allocation, strategic alliances, partnerships and licensing transactions.

Marc has also worked in a number of leadership roles in the financial services and investment banking industries, including Managing Director at Stifel, where he was responsible for building and managing the west coast life sciences and biotechnology investment banking business. He also held roles as Managing Director of Investment Banking in the Global Healthcare Group at UBS, focused on the biotechnology sector, and as Managing Director of Investment Banking at Leerink Swann, where he was instrumental in the west coast expansion of their franchise.

Marc received his medical degree from Johns Hopkins University School of Medicine, where he performed research in molecular oncology. He obtained a Bachelor of Arts degree in molecular biology with honors from Princeton University.